ABCDE criteria and Breslow thickness in cutaneous melanoma (also searched with possessive/alternate eponym spelling where applicable, ICD-10: C43.9) is a cornerstone of dermatological oncology representing the principal clinical screening paradigm and the definitive histological prognostic measurement for malignant melanoma¹. Cutaneous melanoma is an aggressive tumor arising from melanocytes—the pigment-producing cells located predominantly within the basal layer of the epidermis. While accounting for a minority of all skin cancer cases, melanoma is responsible for the vast majority of skin cancer-related deaths globally. Early clinical identification relies heavily on the mnemonic ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter greater than 6 millimeters, and Evolution), which heightens the diagnostic suspicion for malignant transformation in pigmented skin lesions¹. Once a suspicious lesion is excised, histopathological evaluation establishes the Breslow thickness, measuring the tumor's vertical invasion in millimeters from the granular cell layer to the deepest dermal or subcutaneous tumor cells. Breslow thickness dictates surgical margins, the necessity of sentinel lymph node biopsy, overall staging according to the American Joint Committee on Cancer (AJCC), and patient prognosis¹.

Etiology & Risk Factors

• Ultraviolet (UV) Radiation: Cumulative and intermittent intense sun exposure, particularly blistering sunburns during childhood or adolescence, represents the primary environmental etiology driving direct DNA damage, UV-signature mutations (such as C->T transitions), and oncogene activation¹.
• Genetic Susceptibility: Family history of melanoma in a first-degree relative significantly increases risk, linked to high-penetrance germline mutations in susceptibility genes including CDKN2A (p16/INK4a), CDK4, and POT1, as well as moderate-penetrance variants like BAP1 and MITF¹.
• Phenotypic Characteristics: Individuals with fair skin types (Fitzpatrick types I and II), light eye color, red or blond hair, freckling tendencies, and an inability to tan possess a genetically determined higher susceptibility to UV-induced melanocyte carcinogenesis¹.
• Nevus Burden: The presence of numerous common acquired melanocytic nevi (>50–100) or atypical moles (dysplastic nevus syndrome) serves as both an independent risk marker and a structural precursor for malignant melanoma¹.
• Immunosuppression: Chronic immunosuppressive states, such as post-transplant regimens or advanced HIV infection, markedly elevate the incidence and aggressive behavior of cutaneous melanoma¹.

Pathophysiology

Cutaneous melanoma pathogenesis is rooted in the cumulative genomic instability and dysregulation of cellular signaling pathways within epidermal melanocytes. Initial carcinogenic transformation is predominantly triggered by ultraviolet radiation, inducing characteristic DNA mutations that constitutively activate survival and proliferation cascades. A predominant molecular pathway involves activating mutations in the mitogen-activated protein kinase (MAPK) pathway, most notably somatic missense mutations in the BRAF gene (such as the V600E substitution) present in approximately 40% to 50% of cutaneous melanomes, alongside alternative mutations in NRAS, NF1, and KIT¹. Early melanocytic lesions undergo a radial growth phase (RGP), spreading horizontally within the epidermis and papillary dermis without significant metastatic potential. Over time, clones acquire additional genetic hits—such as loss of tumor suppressor genes like PTEN or CDKN2A and telomerase activation—triggering a transition into the vertical growth phase (VGP). In the VGP, tumor cells breach the basement membrane, invading deeply into the reticular dermis and subcutaneous adipose tissue. This deep dermal invasion affords direct access to the dermal lymphatic and microvascular networks, facilitating regional lymph node metastasis and hematogenous dissemination to distant viscera, including the lungs, liver, brain, and bone¹.

Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms: Patients frequently present with a newly developed pigmented skin lesion or, more commonly, a pre-existing mole that has undergone noticeable morphological transformation. While early melanocytes are typically asymptomatic, advanced lesions may present with localized pruritus, tenderness, intermittent bleeding, ulceration, or a palpable subcutaneous nodule¹.
• Physical Examination & Named Clinical Signs: Clinicians evaluate suspicious cutaneous pigmentations using the ABCDE screening framework. Asymmetry indicates that one half of the lesion does not match the other half. Border irregularity manifests as notched, scalloped, or poorly defined peripheral margins. Color variation is characterized by haphazard distributions of multiple shades—including brown, black, tan, red, white, or blue. Diameter greater than 6 mm (the size of a pencil eraser) raises suspicion, though nodular and early melanomas can present smaller. Evolution—defined as any rapid change in size, shape, color, elevation, or symptom development—is the most critical clinical red flag¹. Specialized clinical variants include superficial spreading melanoma (the most common subtype, exhibiting slow radial growth), nodular melanoma (rapidly vertical growth lacking a prominent radial phase), lentigo maligna melanoma (found on chronically sun-damaged skin of elderly patients), and acral lentiginous melanoma (arising on palms, soles, and subungual spaces, unassociated with sun exposure).

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Staging, Classification & Clinical Scoring Systems

Differential Diagnosis

Management & Treatment Protocol

• Initial Stabilization & Resuscitation: Primary cutaneous melanoma rarely causes acute hemodynamic instability at presentation. Ensure comprehensive baseline oncological evaluation, pain control for surgical sites, and psychological support following cancer diagnosis notification¹.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing): For advanced, unresectable, or metastatic melanoma (Stage IV or high-risk resected Stage III), systemic immunotherapy or targeted therapy is indicated. Immune checkpoint inhibitors include pembrolizumab (200 mg IV every 3 weeks or 400 mg IV every 6 weeks for adults) or nivolumab (480 mg IV every 4 weeks), or combination ipilimumab (1 mg/kg IV) plus nivolumab (3 mg/kg IV) every 3 weeks for 4 doses followed by single-agent nivolumab. For BRAF V600 mutation-positive tumors, oral targeted therapy combinations such as dabrafenib (150 mg PO twice daily) plus trametinib (2 mg PO once daily) are administered continuously until disease progression or unacceptable toxicity¹.
• Surgical / Interventional Indications: Definitive primary treatment is surgical wide local excision (WLE). Recommended clinical margins are determined by Breslow thickness: 0.5 cm margins for in-situ melanoma; 1.0 cm margins for Breslow thickness ≤ 1.0 mm; 1.0 to 2.0 cm margins for thickness 1.01 to 2.0 mm; and 2.0 cm margins for thickness > 2.0 mm. Sentinel lymph node biopsy (SLNB) is routinely recommended for melanomas with a Breslow thickness > 0.8 mm or select high-risk T1b lesions to stage regional lymphatic basins accurately¹.

Complications & Prognosis

• Locoregional Complications: Local recurrence, in-transit metastases, satellite lesions, and regional lymphadenopathy causing nerve compression, lymphedema, or tissue necrosis if left untreated¹.
• Systemic Complications: Widespread hematogenous metastasis to critical organs, leading to malignant pleural effusion, bowel obstruction, pathological fractures, and symptomatic brain metastases associated with neurological deficits and increased mortality¹.
• Prognostic Determinants: Breslow thickness is the single most powerful prognosticator for localized disease. Other critical independent prognostic factors include histological ulceration, high mitotic rate (≥ 1/mm²), microsatellitosis, and sentinel lymph node status. 5-year survival rates vary extensively from over 99% for localized thin melanomas (Stage I) down to less than 30% for advanced distant metastatic disease (Stage IV), though modern immune checkpoint blockade and targeted therapies have significantly improved long-term survival outcomes¹.